MapLight Therapeutics (MPLT) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$1.32

Estimate

-$1.31

Surprise

-1.0%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

MapLight Therapeutics (MPLT) reported a wider loss than forecast — diluted EPS of -$1.32 against the -$1.31 estimate (a 1.0% shortfall).

• MapLight Therapeutics Q2 EPS $(1.32) Beats $(1.35) Estimate — benzinga, 2026-08-13
• MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing — benzinga, 2026-08-13

TrendMatrix currently rates MPLT Sell at 5.2/10; no pre/post engine snapshot brackets this report.

0 of the last 4 quarters beat the estimate; this quarter's -1.0% surprise compares with a -569.2% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$13.77

Price target

$23.09

Stop

$12.81

Upside to target

+67.7%

Reward-to-risk

4.5:1

Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$638.6M

P/E (fwd)

-4.2

52-week range

$9.10–$40.43

Off 52-week high

65.9%

RSI (14)

73

Volume vs avg

0.91×

Score today

5.2/10